FDA Reverses on uniQure's Huntington's Disease Gene Therapy, Clearing Q3 2026 BLA Path

In a major regulatory reversal, the FDA has agreed that the 3-year clinical analysis from the Phase I/II study of AMT-130 is an acceptable data package to support a Biologics License Application (BLA) for accelerated approval in Huntington's disease. Following this breakthrough, uniQure has confirmed that it remains on track to submit its BLA in the third quarter of 2026.

This regulatory pathway is highly significant, as Huntington's disease is a devastating, uniformly fatal neurodegenerative disorder with zero disease-modifying therapies currently approved. AMT-130 is an investigational gene therapy designed to silence the huntingtin gene using an adeno-associated virus (AAV5) vector to deliver a microRNA.

Key Regulatory Alignments and Timeline

During its Q2 2026 earnings call on August 7, 2026, uniQure provided critical updates on the program's progress:

FDA Meeting Minutes: Official Type B meeting minutes received in July 2026 confirmed that the FDA and uniQure have formally reached alignment that a BLA submission under the accelerated approval pathway, based on existing 3-year clinical data, is reasonable.
Confirmatory Trial Requirements: The accelerated approval pathway will require uniQure to launch a Phase 3 confirmatory trial, the design of which has been discussed and aligned with the agency.
Four-Year Data Readout: In addition to the BLA submission, uniQure expects to release highly anticipated topline four-year Phase I/II clinical data in September 2026.
Global Expansion: uniQure is also on track to submit a Marketing Authorisation Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) in the third quarter of 2026.

Verbatim Quotes

From Matt Kapusta, Chief Executive Officer of uniQure, during the Q2 2026 earnings release on August 7, 2026:

"Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease."

From the Q2 2026 financial report and earnings presentation:

"Official meeting minutes received in July 2026 confirmed that the FDA and the Company reached alignment that a Biologics License Application (BLA) submission under the accelerated approval pathway for AMT-130, based on the existing clinical data, is reasonable."

Part of

This finding is an example of a pattern recurring across your work:

Leadership churn at regulatory agencies triggers a systemic softening of clinical standards.

The FDA reversed its previous rejection and accepted early Phase I/II data for a gene therapy BLA filing, reflecting a broader trend of regulatory softening following leadership changes.

Rare disease pipelines only accelerate through early FDA alignment and breakthrough designations.

The company accelerated its development pipeline for a fatal rare disease by securing early regulatory alignment on using its Phase I/II data.

Accelerated pathways shift the proof of clinical benefit from pre-market trials to post-marketing requirements.

The FDA bypassed standard pre-market requirements by allowing a gene therapy to proceed to a BLA filing with Phase I/II data on the condition of executing a post-market confirmatory trial.

Revision history